Chi-Med Starts China Phase I Trial of Syk Inhibitor

Hutchison China MediTech (Chi-Med) has begun treating cancer patients in a China Phase I trial of HMPL-523, a novel spleen tyrosine kinase (Syk) inhibitor. The patients have hematological malignancies, including lymphoma and leukemia. In November of last year, Chi-Med reported that an Australian trial of HMPL-523 for arthritis showed a dose-dependent suppression of B-cell activation, with lower rates of diarrhea and hypertension than first-generation Syk inhibitors. More details.... Stock Symbols: (NSDQ/AIM: HCM) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.